Loading...
Images of Hitesh Mahida
(0 from 0 )News
Ranbaxy drops some applications filed with FDA
www.marketwatch.com
[MarketWatch] - Referring to Wednesday's statement, Hitesh Mahida, an analyst at Mumbai-based Fortune Equity Brokers India Ltd., said: "A majority of the products which will be withdrawn are not meaningful in terms of their contribution since these are highly
Pfizer Seen Circling Agila With U.S. Drug Shortages
www.bloomberg.com
[Bloomberg] - The expense of building such sites makes Agila a more attractive acquisition target for a buyer seeking to expand in that area, said Hitesh Mahida, a Mumbai-based analyst at Fortune Equity. “It takes three to four years to set up a plant,” Mahida said
Natco Pharma ties up with Gilead on hepatitis C drug - Times of India
timesofindia.indiatimes.com
· Natco Pharma ties up with Gilead on hepatitis C drug "Natco will now back off its aggressive stance on the patent," said Hitesh Mahida, an analyst at Antique Stock Broking in …
Ranbaxy to Sell Alembic's Anti-Depressant in US - WSJwww.wsj.com › articles
www.wsj.com
Mar 5, · Hitesh Mahida, an analyst at Mumbai-based Fortune Equity Brokers (India) Ltd., said Ranbaxy and Alembic are likely to split profits from the ...
sorted by relevance / date